How close are we to offering treatment tailored to mutational profile?

During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to...

Molecular diagnostics & therapeutics

The AML Hub are pleased to be covering the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting. Here, we review what was...

Editorial theme | The value of FLT3 targeting in AML

FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed by hematopoietic stem and progenitor cells and is involved in the early...

Treating older patients with AML in 2020: What is new and promising?

Interview with Courtney DiNardo, MD Anderson Cancer Center, at the 25th Congress of the EHA about the treatment of elderly patients...

Can CD47 antibody therapy be safely used for AML and MDS?

Podcast discussion between David Sallman, Moffitt Cancer Center, and Naval Daver, MD Anderson Cancer Center, held during the 25th Congress of...

The role of the Nlrp3 inflammasome in hematological pathologies

The Nlrp3 inflammasome has recently gained a lot of attention due to its reported involvement in various hematological pathologies,...

Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak...

AML World Awareness Day 2020 | The value of measurable residual disease in acute myeloid leukemia

Although up to 80% of patients with AML achieve morphologic complete remission (mCR) following...

QUAZAR AML-001 | Updates from EHA 2020

The QUAZAR AML-001 study (NCT01757535) has uncovered the significant clinical activity of CC-486 maintenance in patients aged ≥ 55 with acute myeloid leukemia...

Glasdegib receives approval from the European Commission for the treatment of adult patients with newly diagnosed AML

On June 30, 2020, the European Commission approved glasdegib, an oral smoothened...

VIALE-A trial update | Venetoclax and azacitidine combination for the treatment of older patients with newly diagnosed AML

VIALE-A (NCT02993523) is a randomized, double-blind, multicenter,...

Approaches and emerging therapies for TP53 AML

TP53-mutant AML is an area of unmet need, demonstrating high interpatient heterogeneity. In this podcast with Naval Daver, he describes the efforts being...